Healthcare Industry News: immunotherapy
News Release - July 30, 2015
TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of DirectorsAccomplished Biotech CEO is currently a Strategic Advisor to TapImmune
SEATTLE, July 30, 2015 -- (Healthcare Sales & Marketing Network) -- TapImmune Inc. (TPIV) is pleased to announce the appointment of John N. Bonfiglio, Ph.D., MBA to its Board of Directors. Since February, 2015 Dr. Bonfiglio has been a Strategic Advisor to the management team assisting with financing, development, and implementation of an improved Capital Markets and Shareholder IR/PR program.
Dr. Bonfiglio is a highly successful Biotech CEO with broad experience in corporate strategy, financing, market interactions, and business development. Most recently, Dr. Bonfiglio served as President and CEO of Oragenics, where he refocused the company and raised over $29 million dollars in the public markets while positioning the company for a successful re-listing on the New York Stock Exchange (NYSE). Prior to joining Oragenics, he served as President and CEO of Argos Therapeutics, where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma. As President and CEO of the Immune Response Corporation, he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million), and improved investor relations resulting in a significant appreciation in stock price and shareholder value.
Dr. Bonfiglio also served as President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation's immunotherapy Division.
John received his Ph.D from the University of California, San Diego, and an MBA from Pepperdine University.
Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome John to the TapImmune Board of Directors. For the past six months, John has been working as a strategic advisor to the management team. His input has had a measureable impact on the advances we have made in the areas of investor and shareholder communications, as well as technical and clinical development. As our newest Board member, we look forward to drawing more deeply on his broad experience and success as a biotech executive. His deep industry background will to enhance the overall capabilities of the Board as we enter Phase II clinical trials and the next phase of our growth."
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious disease. The Company's, peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.